Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer (24 September 2024)

Summary

A major clinical trial, led by the University of Sheffield, has revealed survival rates for patients with operable bladder cancer are significantly improved by adding an immunotherapy drug to before and after surgery.